ANXA10 (Annexin A10) is a member of the annexin family of calcium-dependent phospholipid-binding proteins, which are implicated in membrane organization, intracellular signaling, and vesicular trafficking. Unlike other annexins, ANXA10 lacks a conserved N-terminal domain, contributing to its unique functional properties. It is primarily expressed in the gastrointestinal tract, liver, and gallbladder, with emerging roles in cellular differentiation, proliferation, and apoptosis.
Research has linked ANXA10 to several pathological conditions, particularly cancers. It is frequently downregulated or epigenetically silenced in gastric, hepatocellular, and colorectal carcinomas, suggesting a potential tumor-suppressive role. Conversely, ANXA10 overexpression has been observed in subsets of pancreatic and ovarian cancers, highlighting context-dependent functions. Its dysregulation is associated with disease progression, metastasis, and chemoresistance, making it a candidate biomarker for prognosis and therapeutic targeting.
ANXA10 antibodies are critical tools for detecting protein expression in tissues or cell lysates via techniques like immunohistochemistry (IHC) and Western blot. These antibodies aid in studying ANXA10's spatial distribution, expression patterns in normal versus diseased states, and its interaction partners. Commercially available monoclonal and polyclonal ANXA10 antibodies are validated for specificity, though variability in epitope recognition necessitates careful selection based on experimental applications. Ongoing research focuses on elucidating ANXA10's molecular mechanisms and clinical utility, particularly in precision oncology and biomarker-driven therapies.